Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Niagen Bioscience, Inc.CDXC · Entity 6146 | EXECUTIVE VICE PRESIDENT | January 21, 2018 | January 23, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Niagen Bioscience, Inc.
Report date January 21, 2018 · Filed January 23, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.85 · Expires 2028-01-21 | Direct | 120,000 |
Reported balance
After 2018-01-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-21 · Grant · Acquired 120,000 · Balance 120,000 F1: Options vest 25% on January 21, 2019 and thereafter 1/48th vest each month. |
Filing footnotes · ownership attribution and instrument terms
F1: Options vest 25% on January 21, 2019 and thereafter 1/48th vest each month.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 21, 2018 Filed Jan 23, 2018 21:22 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 120,000 | $0.00 Strike: $5.85 | $0.00 |
DisclosureSEC source: 0001415889-18-000108 · form4-01232018_010110.xml · derivative · entry 1 Rhonemus Troy Allen · CIK 0001601604 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2028-01-21 F1 · derivative.exercise_date: Options vest 25% on January 21, 2019 and thereafter 1/48th vest each month. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.